Inflammation and tuberculosis: Host-directed therapies

Journal of Internal Medicine

Volumn 277, Issue 4, 2015, Pages 373-387

  Zumla, A ^a   Rao, M ^b   Parida, S K ^b   Keshavjee, S ^c   Cassell, G ^c   Wallis, R ^d   Axelsson Robertsson, R ^b,e   Doherty, M ^f   Andersson, J ^b   Maeurer, M J ^b,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f GLAXOSMITHKLINE   (Denmark)

Author keywords

Drug resistant tuberculosis; Host directed therapy; Inflammation; M. tuberculosis; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

ANTIINFLAMMATORY AGENT; APRIL PROTEIN; B CELL ACTIVATING FACTOR; BCG VACCINE; CLOFAZIMINE; CYCLOOXYGENASE 2 INHIBITOR; DIAZOXIDE; HISTONE DEACETYLASE INHIBITOR; HLA DR ANTIGEN; IBUPROFEN; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 7; LEUKOTRIENE A4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BCL 2; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ANTIMICROBIAL THERAPY; B LYMPHOCYTE; BACTERIAL CLEARANCE; CELL THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; GENDER; GENE EXPRESSION; GENE MUTATION; HOST CELL; HOST DIRECTED THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCING CELL; INFLAMMATION; MACROPHAGE; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REINFECTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; TUBERCULOSIS; CELLULAR IMMUNITY; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

HISTONE DEACETYLASE INHIBITORS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84925365327     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12256     Document Type: Review

References (140)

1. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the EU - a systematic analysis and cost calculation. Eur Respir J 2013; 43: 554.
2. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11: 343-54.
3. Muthuswamy P, Hu TC, Carasso B, Antonio M, Dandamudi N. Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature. Chest 1995; 107: 1621-30.
4. Azzurri A, Kanaujia GV, Sow OY et al. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. Int J Immunopathol Pharmacol 2006; 19: 199-208.
5. Ashenafi S, Aderaye G, Zewdie M et al. BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients. Thorax 2013; 68: 269-76.
6. Gaseitsiwe S, Valentini D, Mahdavifar S et al. Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS One 2008; 3: e3840.
7. Cliff JM, Lee JS, Constantinou N et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013; 207: 18-29.
8. Valentini D, Gaseitsiwe S, Maeurer M. Humoral 'reactome' profiles using peptide microarray chips. Trends Immunol 2010; 31: 399-400.
9. Liu K, Zhang Y, Hu S et al. Increased levels of BAFF and APRIL related to human active pulmonary tuberculosis. PLoS One 2012; 7: e38429.
10. Cross AH, Klein RS, Piccio L. Rituximab combination therapy in relapsing multiple sclerosis. Ther Adv Neurol Disord 2012; 5: 311-9.
11. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-α, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010; 5: e12365.
12. Eilertsen GO, Van Ghelue M, Strand H, Nossent JC. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology 2011; 50: 2197-205.
13. Doreau A, Belot A, Bastid J et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-85.
14. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010; 21: 455-62.
15. Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369-77.
16. Cruz A, Fraga AG, Fountain JJ et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207: 1609-16.
17. Basile JI, Geffner LJ, Romero MM et al. Outbreaks of Mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. J Infect Dis 2011; 204: 1054-64.
18. Yamada G, Shijubo N, Shigehara K, Okamura H, Kurimoto M, Abe S. Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000; 161: 1786-9.
19. Barnes PF. Immunotherapy for tuberculosis: wave of the future or tilting at windmills? Am J Respir Crit Care Med 2003; 168: 142-3.
20. Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191: 856-65.
21. Vudattu NK, Magalhaes I, Hoehn H, Pan D, Maeurer MJ. Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun 2009; 10: 132-40.
22. Rane L, Rahman S, Magalhaes I et al. Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue. Genes Immun 2011; 12: 513-22.
23. Maeurer MJ, Trinder P, Hommel G et al. Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice. Infect Immun 2000; 68: 2962-70.
24. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013; 368: 299-302.
25. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010; 125: S272-83.
26. Vudattu NK, Magalhaes I, Schmidt M, Seyfert-Margolis V, Maeurer MJ. Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer 2007; 121: 1512-9.
27. Seitzer U, Kayser K, Hohn H et al. Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology 2001; 104: 269-77.
28. Axelsson-Robertson R, Loxton AG, Walzl G et al. A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis. PLoS One 2013; 8: e58309.
29. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M. The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 2012; 205(Suppl 2): S301-15.
30. Omar H, Ahmed R, Rane L et al. Decreased IL-7 signaling in T cells from patients with PTLD after allogeneic HSCT. J Immunother 2011; 34: 390-6.
31. Chiu YW, Weng YH, Lo HL, Shih YH, Hsu CC, Kuo KN. Comparison of accessing online databases between physicians and nurses in Taiwan. Inform Health Soc Care 2012; 37: 230.
32. Gomes MG, Aguas R, Lopes JS et al. How host heterogeneity governs tuberculosis reinfection? Proc Biol Sci 2012; 279: 2473-8.
33. Yew WW, Leung CC. Are some people not safer after successful treatment of tuberculosis? Am J Respir Crit Care Med 2005; 171: 1324-5.
34. Austin JF, Dick JM, Zwarenstein M. Gender disparity amongst TB suspects and new TB patients according to data recorded at the South African Institute of Medical Research laboratory for the Western Cape Region of South Africa. Int J Tuberc Lung Dis 2004; 8: 435-9.
35. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-93.
36. Hoal EG, Lewis LA, Jamieson SE et al. SLC11A1 (NRAMP1) but not SLC11A2 (NRAMP2) polymorphisms are associated with susceptibility to tuberculosis in a high-incidence community in South Africa. Int J Tuberc Lung Dis 2004; 8: 1464-71.
37. Gomes MG, Franco AO, Gomes MC, Medley GF. The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy. Proc Biol Sci 2004; 271: 617-23.
38. Jasmer RM, Bozeman L, Schwartzman K et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-6.
39. Bang D, Andersen AB, Thomsen VO, Lillebaek T. Recurrent tuberculosis in Denmark: relapse vs. re-infection. Int J Tuberc Lung Dis 2010; 14: 447-53.
40. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 223-37.
41. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011; 9: 415-30.
42. Meintjes G, Skolimowska KH, Wilkinson KA et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012; 186: 369-77.
43. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol 2010; 185: 15-22.
44. Mudenda V, Lucas S, Shibemba A et al. Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. J Infect Dis 2012; 205(Suppl 2): S340-6.
45. Marais BJ, Lonnroth K, Lawn SD et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013; 13: 436-48.
46. Brodin P, Valentini D, Uhlin M, Mattsson J, Zumla A, Maeurer MJ. Systems level immune response analysis and personalized medicine. Expert Rev Clin Immunol 2013; 9: 307-17.
47. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012; 205(Suppl 2): S325-34.
48. Zumla A, Maeurer M. Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. J Infect Dis 2012; 205(Suppl 2): S335-9.
49. Bilaceroglu S, Perim K, Buyuksirin M, Celikten E. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Int J Tuberc Lung Dis 1999; 3: 47-54.
50. Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18: 257-64.
51. Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-97.
52. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2: 506-15.
53. Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678-81.
54. Henter JI, Palmkvist-Kaijser K, Holzgraefe B, Bryceson YT, Palmer K. Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010; 376: 2116.
55. Harari A. Dominant TNF-α+Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011; 17: 372-6.
56. Johnson BJ, Bekker LG, Rickman R et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997; 78: 195-203.
57. Grahmann PR, Braun RK. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. Int J Tuberc Lung Dis 2008; 12: 636-44.
58. Tobin DM, Roca FJ, Oh SF et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148: 434-46.
59. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci 2010; 293: 12-7.
60. Jacobsen M, Repsilber D, Kleinsteuber K et al. Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosisTB patients. Clin Microbiol Infect 2011; 17: 1323-31.
61. Masood KI, Rottenberg ME, Salahuddin N et al. Expression of M. tuberculosis -induced suppressor of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and secretion of IL-6 associates with differing clinical severity of tuberculosis. BMC Infect Dis 2013; 13: 13.
62. Magalhaes I, Vudattu NK, Ahmed RK et al. High content cellular immune profiling reveals differences between rhesus monkeys and men. Immunology 2010; 131: 128-40.
63. Mattos AM, Almeida Cde S, Franken KL et al. Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol 2010; 22: 775-82.
64. Veenstra H, Crous I, Brahmbhatt S et al. Changes in the kinetics of intracellular IFN-gamma production in TB patients during treatment. Clin Immunol 2007; 124: 336-44.
65. Sutherland JS, Hill PC, Adetifa IM et al. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS One 2011; 6: e25230.
66. Schleicher GK, Herbert V, Brink A et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005; 25: 688-92.
67. Djoba Siawaya JF, Bapela NB, Ronacher K et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect 2008; 56: 340-7.
68. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-7.
69. Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012; 36: 514-32.
70. Wolf AJ, Linas B, Trevejo-Nunez GJ et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007; 179: 2509-19.
71. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One 2006; 1: e43.
72. Das B, Kashino SS, Pulu I et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013; 5: 170ra13.
73. Bermudez LE, Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 1996; 64: 1400-6.
74. Bradfute SB, Castillo EF, Arko-Mensah J et al. Autophagy as an immune effector against tuberculosis. Curr Opin Microbiol 2013; 16: 355-65.
75. Behar SM, Martin CJ, Booty MG et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol 2011; 4: 279-87.
76. Castillo EF, Dekonenko A, Arko-Mensah J et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci USA 2012; 109: E3168-76.
77. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99-109.
78. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-68.
79. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013; 21: 277-85.
80. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003; 983: 84-100.
81. Han BR, You BR, Park WH. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncol Rep 2013; 30: 2999-3005.
82. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 2010; 12: 328-40.
83. Dowdell KC, Pesnicak L, Hoffmann V et al. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 2009; 37: 487-94.
84. Hideshima T, Anderson KC. Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol 2013; 97: 324-32.
85. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
86. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009; 107: 600-8.
87. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799-806.
88. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-8.
89. Yang HC, Xing S, Shan L et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Investig 2009; 119: 3473-86.
90. Shan L, Deng K, Shroff NS et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
91. Rasmussen TA, Tolstrup M, Winckelmann A, Ostergaard L, Sogaard OS. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 2013; 9: 790-9.
92. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013; 368: 651-62.
93. Eichelmann K, Gonzalez Gonzalez SE, Salas-Alanis JC, Ocampo-Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr 2013; 104: 554-63.
94. Fukutomi Y, Maeda Y, Makino M. Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother 2011; 55: 4000-5.
95. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-7.
96. Grosset JH, Tyagi S, Almeida DV et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188: 608-12.
97. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-93.
98. Yoo JW, Lyu J, Lee SD, Kim WS, Kim DS, Shim TS. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence]. Int J Tuberc Lung Dis 2013; 17: 1243-4.
99. Zhang J, Jiang R, Takayama H, Tanaka Y. Survival of virulent Mycobacterium tuberculosis involves preventing apoptosis induced by Bcl-2 upregulation and release resulting from necrosis in J774 macrophages. Microbiol Immunol 2005; 49: 845-52.
100. Kumar D, Rao KV. Regulation between survival, persistence, and elimination of intracellular mycobacteria: a nested equilibrium of delicate balances. Microbes Infect 2011; 13: 121-33.
101. Messmer UK, Reed UK, Brune B. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J Biol Chem 1996; 271: 20192-7.
102. Hogdal LJ, Letai A. BCL-2 inhibition: stemming the tide of myeloid malignancies. Cell Stem Cell 2013; 12: 269-70.
103. Lagadinou ED, Sach A, Callahan K et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329-41.
104. Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. Inflammasomes and host defenses against bacterial infections. Curr Opin Microbiol 2013; 16: 23-31.
105. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009; 21: 10-6.
106. Ashida H, Mimuro H, Ogawa M et al. Cell death and infection: a double-edged sword for host and pathogen survival. J Cell Biol 2011; 195: 931-42.
107. Wong KW, Jacobs WR Jr. Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis. Cell Microbiol 2011; 13: 1371-84.
108. Dorhoi A, Nouailles G, Jorg S et al. Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis. Eur J Immunol 2012; 42: 374-84.
109. Briken V, Ahlbrand SE, Shah S. Mycobacterium tuberculosis and the host cell inflammasome: a complex relationship. Front Cell Infect Microbiol 2013; 3: 62.
110. Master SS, Rampini SK, Davis AS et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 2008; 3: 224-32.
111. Mishra BB, Rathinam VA, Martens GW et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 2013; 14: 52-60.
112. Verway M, Bouttier M, Wang TT et al. Vitamin D induces interleukin-1beta expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog 2013; 9: e1003407.
113. Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013; 38: 1142-53.
114. Coetzee WA. Multiplicity of effectors of the cardioprotective agent, diazoxide. Pharmacol Ther 2013; 140: 167-75.
115. Tobin DM, Vary JC Jr, Ray JP et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010; 140: 717-30.
116. Tobin DM, Ramakrishnan L. TB: the Yin and Yang of lipid mediators. Curr Opin Pharmacol 2013; 13: 641-5.
117. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
118. Manca C, Koo MS, Peixoto B, Fallows D, Kaplan G, Subbian S. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS One 2013; 8: e74082.
119. Tsenova L, Mangaliso B, Muller G et al. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002; 46: 1887-95.
120. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013; 188: 600-7.
121. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013; 58: 574.
122. Guzman JD, Evangelopoulos D, Gupta A et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013; 3: pii: e002672. doi: 10.1136.
123. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013; 208: 199-202.
124. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-64.
125. Napier RJ, Rafi W, Cheruvu M et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011; 10: 475-85.
126. Dorhoi A, Desel C, Yeremeev V et al. The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med 2010; 207: 777-92.
127. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today 1997; 18: 292-9.
128. Seok J, Warren HS, Cuenca AG et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-12.
129. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in Melanoma. New Engl J Med 2013; 369: 134-44.
130. Rao V, Gao F, Chen B, Jacobs WR Jr, Glickman MS. Trans-cyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis -induced inflammation and virulence. J Clin Investig 2006; 116: 1660-7.
131. Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5: 717-27.
132. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
133. Desai CR, Heera S, Patel A, Babrekar AB, Mahashur AA, Kamat SR. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J Assoc Physicians India 1989; 37: 694-7.
134. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 1999; 43: 1285-8.
135. Lin PL, Dartois V, Johnston PJ et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA 2012; 109: 14188-93.
136. Skrahin A, Ahmed R, Ferrara G et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014; 2: 108-22.
137. Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012; 7: e47559.
138. Marais BJ, Graham SM, Maeurer M, Zumla A. Progress and challenges in childhood tuberculosis. Lancet Infect Dis 2013; 13: 287-9.
139. Byrne ST, Denkin SM, Zhang Y. Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob Agents Chemother 2007; 51: 794-5.
140. Dranoff G. Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. Nat Med 2013; 19: 1100-1.